JP2022527322A5 - - Google Patents
Info
- Publication number
- JP2022527322A5 JP2022527322A5 JP2021558523A JP2021558523A JP2022527322A5 JP 2022527322 A5 JP2022527322 A5 JP 2022527322A5 JP 2021558523 A JP2021558523 A JP 2021558523A JP 2021558523 A JP2021558523 A JP 2021558523A JP 2022527322 A5 JP2022527322 A5 JP 2022527322A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- protein according
- optionally
- mutations
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067565A JP2025111546A (ja) | 2019-03-28 | 2025-04-16 | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825579P | 2019-03-28 | 2019-03-28 | |
| US62/825,579 | 2019-03-28 | ||
| PCT/US2020/025419 WO2020198659A1 (en) | 2019-03-28 | 2020-03-27 | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067565A Division JP2025111546A (ja) | 2019-03-28 | 2025-04-16 | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527322A JP2022527322A (ja) | 2022-06-01 |
| JP2022527322A5 true JP2022527322A5 (enExample) | 2023-04-03 |
| JP7749186B2 JP7749186B2 (ja) | 2025-10-06 |
Family
ID=72608957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558523A Active JP7749186B2 (ja) | 2019-03-28 | 2020-03-27 | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 |
| JP2025067565A Pending JP2025111546A (ja) | 2019-03-28 | 2025-04-16 | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067565A Pending JP2025111546A (ja) | 2019-03-28 | 2025-04-16 | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220185857A1 (enExample) |
| EP (1) | EP3946409A4 (enExample) |
| JP (2) | JP7749186B2 (enExample) |
| CN (1) | CN113645988A (enExample) |
| CA (1) | CA3133830A1 (enExample) |
| WO (1) | WO2020198659A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| CN114606227B (zh) * | 2022-02-22 | 2024-03-08 | 复旦大学 | 高精度腺嘌呤碱基编辑器及其应用 |
| WO2025059390A2 (en) * | 2023-09-12 | 2025-03-20 | Heligenics Inc. | Engineered interferon-beta proteins |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294331B2 (en) * | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
| US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
| RO120919B1 (ro) | 1996-10-25 | 2006-09-29 | G.D. Searle & Co. | Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei |
| US6660257B1 (en) * | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| US6291661B1 (en) * | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
| US20050232931A1 (en) * | 2003-06-13 | 2005-10-20 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| CA2528595A1 (en) | 2003-06-13 | 2005-01-06 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| AU2013211059B8 (en) * | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| US10308697B2 (en) * | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| WO2017099474A1 (ko) * | 2015-12-08 | 2017-06-15 | 연세대학교 산학협력단 | ＧＭ－ＣＳＦ 유전자; FLT3L-TRAIL 융합 유전자; ＴＧＦ－β 발현을 억제하는 ｓｈＲＮＡ; 및 HSP 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물 |
| EP4276114A3 (en) | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
-
2020
- 2020-03-27 CA CA3133830A patent/CA3133830A1/en active Pending
- 2020-03-27 WO PCT/US2020/025419 patent/WO2020198659A1/en not_active Ceased
- 2020-03-27 CN CN202080025812.5A patent/CN113645988A/zh active Pending
- 2020-03-27 EP EP20778984.3A patent/EP3946409A4/en active Pending
- 2020-03-27 US US17/442,772 patent/US20220185857A1/en active Pending
- 2020-03-27 JP JP2021558523A patent/JP7749186B2/ja active Active
-
2025
- 2025-04-16 JP JP2025067565A patent/JP2025111546A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akhlynina et al. | Nuclear targeting of chlorin e6 enhances its photosensitizing activity | |
| RU2481398C2 (ru) | Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция | |
| US10967038B2 (en) | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases | |
| ES2676630T3 (es) | Control inmunogénico de tumores y células tumorales | |
| US20030194739A1 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| EP2627346B1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis | |
| WO2004026897A1 (ja) | Ｗｔ１置換型ペプチド | |
| JP2021522861A (ja) | インターロイキン ２突然変異タンパク質およびｉ型インターフェロンで構成される融合タンパク質 | |
| JP2025111546A5 (enExample) | ||
| JP2023538071A5 (enExample) | ||
| JP2023522588A5 (enExample) | ||
| US8303957B2 (en) | Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof | |
| JP2024513559A5 (enExample) | ||
| Pechar et al. | Coiled coil peptides as universal linkers for the attachment of recombinant proteins to polymer therapeutics | |
| JP2018507689A5 (enExample) | ||
| JP2022542448A5 (enExample) | ||
| CN104619333A (zh) | 经修饰的肽,cb受体的配体,用于评估与cb受体结合的试剂盒、体外方法,用于调节cb受体活性的药物组合物、用途 | |
| Behi et al. | Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein | |
| CN1157570A (zh) | 化学药物向特定细胞的细胞内载运 | |
| WO2023138573A1 (zh) | 白细胞介素21及其受体复合物 | |
| CN116375880A (zh) | 融合蛋白及其制备方法和应用 | |
| JP5189593B2 (ja) | 無差別ＨＥＲ−２／ＮｅｕＣＤ４Ｔ細胞エピトープ | |
| CN116836261A (zh) | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 | |
| CN114931651B (zh) | 一种基于抗体IgG1-Fc结构域的靶向-药物及其制备方法与应用 | |
| AU2012227350C1 (en) | HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same |